FDA 483 OBSERVATION · #292 OF 1,923 MOST-CITED

Procedures To Be in Writing

FDA cited this observation 99 times across 96 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Drugs99
BY FISCAL YEAR
FY20265
FY20253
FY20245
FY20233
FY20227
FY20215
FY20206
FY201917
FY201814
FY201717
FY201617

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5× the rate of the average FDA-cited firm (38.5% vs 7.8%), across 96 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Written procedures are lacking which describe in sufficient detail the identification, storage, testing, approval and rejection of components, drug product containers and closures.

The Flower Remedy LLC · Englewood, Colorado · Drugs · 2026-06-12

Written procedures are lacking which describe in sufficient detail the testing of components.

GVS TM, Inc · Covina, California · Drugs · 2026-05-01

Written procedures are lacking which describe in sufficient detail the receipt, testing, approval and rejection of components and drug product containers.

Aphena Pharma Solutions - Maryland, LLC · Easton, Maryland · Drugs · 2026-02-20

Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components, drug product containers and closures.

NexCell Scientific Inc · Irvine, California · Drugs · 2026-02-05

Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components and drug product containers.

Bello Bio LLC · Scottsdale, Arizona · Drugs · 2025-12-16

Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components, drug product containers and closures.

Lexia LLC · Franklin, Tennessee · Drugs · 2025-09-29

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality system →Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →